William Jagust, MD

Professor of Public Health and Neuroscience

University of California, Berkeley

Dr. William Jagust is a Professor of Public Health and Neuroscience at the University of California, Berkeley, and a Faculty Senior Scientist at Lawrence Berkeley National Laboratory. He was previously the Chair of the Department of Neurology at the University of California, Davis and founding director of the UC Davis Alzheimer's Disease Center. Dr. Jagust's career has been focused on understanding the aging brain, and particularly the borderland between normal cognitive aging and Alzheimer's disease. His laboratory has pioneered in the use of multimodal imaging to understand brain aging and Alzheimer's disease, employing positron emission tomography (PET) to measure β-amyloid and tau proteins in the brain, and magnetic resonance imaging (MRI) to investigate how these protein aggregates affect neural function and structure. He has served on editorial boards of major journals, advisory boards to the National Institute on Aging, and to the pharmaceutical industry. His laboratory leads the PET component of numerous multicenter studies including the Alzheimer's Disease Neuroimaging Initiative, the POINTER imaging study, SCAN, and the HEAD project. He is a recipient of the 2013 Potamkin Prize for Research in Pick's, Alzheimer's and Related Diseases.



Venkata SatyAnand Mattay, MD

Lead Physician

DIRM/OSM/CDER/OND

Dr. Venkata SatyAnand Mattay is a Lead Physician in FDA's Division of Imaging and Radiation Medicine. As a Lead Physician, he manages a team of Imaging Medical Officers and serves as a clinical expert on a multidisciplinary team in the review and evaluation of scientific data to assess imaging products and provide advice to sponsors throughout the imaging product development process. He is board certified in both Neurology and Nuclear Medicine. Prior to joining the FDA in 2019, Dr. Mattay served as the Director of the Neuroimaging Core Facility of the Genes, Cognition and Psychosis Program at the NIMH, and as Director of the Neuroimaging Core at the Lieber Institute for Brain Development. Dr. Mattay has been the recipient of multiple awards in recognition and appreciation of sustained high quality work performance.

Victor L. Villemagne, M.D.

Professor of Psychiatry

Aging Mind Foundation Fellow

Co-Director, Molecular Biomarkers in Psychiatry

Department of Psychiatry
The University of Pittsburgh

Prof Villemagne graduated *Cum Laude* in 1983 from the Universidad Nacional de Buenos Aires, Argentina. He was awarded a Post-Doctoral Fellowship in Nuclear Medicine in 1984 and continued his post-graduate studies at the Division of Nuclear Medicine at The Johns Hopkins Medical Institutions.

In 2003 he joined the Neurodegeneration group in Melbourne, where he performed several preclinical and clinical studies of new tracers for amyloid and tau imaging, and in 2020, he joined the Dept of Psychiatry at the University of Pittsburgh. With an h-index of 77, he has authored or co-authored several book chapters, requested reviews, and more than 400 original research publications. Among other honors, he has received the de Leon Prize in Neuroimaging (Boston, USA, 2013), the Christopher Clark Award for the Continuing Advancement in the Field of Human Amyloid Imaging, (Miami, USA, 2014), the Kuhl-Lassen award by the Society of Nuclear Medicine (Philadelphia, USA, 2018), and the Aging Mind Foundation Award (2022). Since 2016 he has been recognized as one of The World's Most Influential Scientific Minds based on his citations being in the top 1% in the world in the field of Neuroscience.

Gil Rabinovici, MD

Edward Fein & Pearl Landrith Distinguished Professor

Departments of Neurology, Radiology and Biomedical Imaging, University of California, San Francisco (UCSF)

Dr. Rabinovici received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed neurology residency, chief residency and behavioral neurology fellowship at UCSF. Dr. Rabinovici's work investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative. He is Director of the UCSF Alzheimer's Disease Research Center, study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies (~25,000 total participants), as well as co-PI on the emerging Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) and PI on several additional national and local studies focused on AD and related disorders. Dr. Rabinovici's research is supported by NIH, Alzheimer's Association, American College of Radiology, Rainwater Charitable Foundation, Shenandoah Foundation and industry partners. Previous awards include the 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging, 2015 Christopher Clark Award in Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 deLeon Prize from the Alzheimer's Association.

Phillip Kuo, M.D., Ph.D.

Professor

University of Arizona

Phillip Kuo graduated in chemistry from Harvard and then earned an MD/PhD from the University of Virginia. Post-graduate training included residency in Internal Medicine at UCLA, fellowship in Nuclear Medicine and residency in Radiology at Yale. He is Professor of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona, where he served as Chief of Nuclear Medicine for 10 years.

Scientific interests span basic, translational, and clinical research. His more than 100 peer-reviewed publications span quantification, performance and interpretation, initial diagnosis as well as monitoring response, and policy. He has served as principal investigator/co-PI on numerous investigator-initiated trials and NIH grants for development of hardware and software. Scope of experience includes designing and conducting phase I, 2 and 3 clinical trials and development of novel read methodologies. For clinical trials, he has read over ten thousand PET scans for Alzheimer's disease.

Dan Krainak, Ph.D.

Assistant Director

Magnetic Resonance and Nuclear Medicine Team

DHT8C: Division of Radiological Imaging & Radiation Therapy Devices

OPEQ | OHT8: Office of Radiological Health

CDRH | U.S. Food and Drug Administration

Dan Krainak is the Assistant Director for the Magnetic Resonance and Nuclear Medicine devices team in CDRH. Dan joined the FDA in 2011 and has participated in the review of radiological devices, imaging biomarkers, and radiological imaging in therapeutic medical product clinical trials.

Susan Landau, PhD

Research neuroscientist

Helen Wills Neuroscience Institute, University of California Berkeley

Susan Landau is Research Neuroscientist in the Helen Wills Neuroscience Institute at the University of California, Berkeley. Her research focuses on understanding the risk factors and pathophysiology involved in the earliest stages of Alzheimer's disease, with an emphasis on amyloid and tau biomarkers. She is principal investigator of POINTER Imaging, which is examining the effects of lifestyle interventions on Alzheimer's disease brain biomarkers in at-risk older adults. She works in the PET Imaging Core for several other multisite studies and trials, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ADNI Late Life Depression Study, and the Standardized Centralized Alzheimer's & Related Dementias Neuroimaging (SCAN) study.

C. David Cooke, MSEE

Director, Clinical Applications

Syntermed, Inc.

Mr. Cooke has been with Syntermed since 2004, where he is currently serving as the Director of Clinical Applications. In this role he is responsible for developing, defining and driving clinical application strategies. He also works part-time for the Emory University Nuclear Cardiology R&D laboratory; a position he has held for 35 years. He has served as one of the main software developers for both NeuroQ and the Emory Cardiac Toolbox, and has worked on all aspects of the design and development of both applications. He also has extensive experience in working with 3rd party vendors to successfully deploy both clinical applications to end users. His dual positions at Syntermed and Emory give him the unique and invaluable opportunity of seeing and experiencing both the academic and commercial side of software design, development and deployment. Mr. Cooke received his Master of Science in Electrical Engineering degree from the Georgia Institute of Technology in 1987, and has authored or co-authored 17 book chapters, 64 manuscripts and 109 abstracts.

Juan Domingo GISPERT, PhD

Group Leader – Neuroimaging.

Barcelonabeta Brain Research Center
Spanish National Center for Cardiovascular Research

I hold a PhD in Telecommunication Engineering and a Master's in Biomedical Engineering. My main field of research is the development and use of analytical techniques for brain imaging modalities. In the last decade, my research has been focused on studying the pathophysiological processes involved in the preclinical stages of Alzheimer's disease (AD) to inform preventive interventions. Recently, I have also become interested in the impact of cardiovascular risk factors on the brain of middle-aged healthy individuals.

I was awarded a Ramon y Cajal Fellowship in 2013 and, in 2019, received the I3 certificate of outstanding research trajectory by the Spanish Ministry of Science and Innovation. I teach courses on Medical Imaging at the Pompeu Fabra University in Barcelona in the degrees of Biomedical Engineering and Human Biology. I have supervised 5 PhD Theses (one outstanding award of the Faculty of Medicine of the University of Barcelona) and I'm currently supervising 5 more. I supervised 5 postdoctoral researchers that have been awarded national, European, and American fellowships.

Val J. Lowe, MD

Professor of Radiology

Mayo Clinic, Rochester, MN

Val J. Lowe, MD is a Professor of Radiology at Mayo Clinic, Rochester, Minnesota, USA, and is the director of the Mayo Clinic Molecular Imaging Resource. Dr. Lowe has served on numerous NIH review committees and panels. He has over 400 peer-reviewed publications, several patents and has active funding through 20 NIH grants to study imaging. He has served as the Chair of the World Molecular Imaging Society and is an elected fellow of the Society. He has been active in PET education and development clinical applications for PET. He was instrumental in the approval of clinical PET imaging in the United States by the FDA and Medicare. Dr. Lowe's lab does PET radiotracer development, preclinical imaging, and human imaging for a wide range of diseases. Dr. Lowe and research collaborators at Mayo Clinic have multiple projects evaluating the utility of PET and MRI multimodality brain imaging in neurodegenerative disease and aging and test imaging as a way to evaluate populations for prediction, diagnosis, prevention, and therapy of neurodegenerative disease.

Mark A. Mintun, MD

Senior Vice-President of Pain and Neurodegeneration Research and Clinical Development, Eli Lilly and Company, Indianapolis, IN

President, Avid Radiopharmaceuticals, Inc. Philadelphia, PA

Mark A. Mintun, MD has led Pain and Neurodegeneration Research and Clinical Development since January of 2018. In 2010, Dr. Mintun joined Avid Radiopharmaceuticals, now a wholly owned subsidiary of Eli Lilly & Co., as Chief Medical Officer and became its President in 2014. Prior to Avid, Dr. Mintun was Professor and Vice-Chair of Radiology at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine, with joint appointments in Psychiatry, Neurology, Bioengineering, and the Anatomy and Neurobiology Departments. He earned a BS in Chemical Engineering from the Massachusetts Institute of Technology in 1977, received his medical degree in 1981 at Washington University School of Medicine and completed a research fellowship in neurology and residency training in nuclear medicine. Dr. Mintun has co-authored over 200 research publications that include reports of brain imaging to characterize flow/metabolism relationships, neurotransmitter systems, circuitry for processing affective stimuli and the pathology of neurodegenerative diseases. After joining Avid he led development programs for both amyloid and tau imaging of patients with neurodegenerative diseases. More recently he has overseen the extensive research and early phase development programs for Alzheimer disease, Parkinson disease, Migraine and Chronic Pain conditions.

Gill Farrar, PhD
Global Medical Leader Neurology
GE Healthcare

Has worked in the PET Amyloid Imaging field for 20 years starting off with a collaboration with Chet Mathis and Bill Klunk to develop a fluorine-18 version of Pittsburgh compound B. In the first instance I led teams which completed all the R+D and NDA and MAA registration work for Vizamyl (Flutemetamol) and once approved moved into Medical Affairs as Global Medical Leader for PET Neurology to provide education and support to both research and routine clinical users. Most recently I headed up (with Frederik Barkhof) the European AMYPAD consortium which has just completed and collected over 3500 amyloid PET images in two large clinical studies and has provided unique insights into quantification methodology of amyloid PET.

Andrew Stephens, MD, PhD

Chief Medical Officer

Andrew Stephens, MD, PhD

Chief Medical Officer

Dr. Stephens has more than 30 years of experience in the pharmaceutical industry, primarily in the areas of neurodegenerative diseases, oncology and diagnostic imaging. Previously, he was Chief Medical Officer at Piramal Imaging and the VP Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. He has held positions of increasing responsibility at NeXagen/NeXstar, Gilead, Schering AG, and OSI Pharmaceuticals.

He received his BA cum laude in chemistry from the University of Colorado, Boulder. He also received an MD with honors and a PhD in biochemistry, biophysics and genetics from the University of Colorado, Boulder. Dr. Stephens is Board certified in Internal Medicine and had a clinical practice before entering pharmaceutical development.

Maria Carrillo, PhD

Chief Science Officer

Alzheimer's Association

As chief science officer, Maria C. Carrillo, Ph.D., sets the strategic vision for the Alzheimer's Association global research program. Under her leadership, the Association is the world's largest nonprofit funder of Alzheimer's research — currently investing over $250 million — and an internationally recognized pioneer in convening the dementia science community. Dr. Carrillo uses her platform as a noted public speaker to play an instrumental role in the Association's efforts to lobby for increased funding for the disease.

Dr. Carrillo oversees the implementation of the Association's growing portfolio of research initiatives, including the Alzheimer's Association International Conference® (AAIC®), the world's largest and most influential dementia science meeting, and the Research Roundtable, which enables international scientific, industry and government leaders to work together to overcome shared obstacles in Alzheimer's science and drug development. In addition, she leads the Association's direct involvement in research by serving as a co-primary investigator for the Association-funded and led U.S. POINTER study, a lifestyle intervention trial to prevent cognitive decline and dementia.

Dr. Carrillo earned her Ph.D. from Northwestern University's Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer's brain imaging and risk factors at Rush University Medical Center in Chicago.

Stephen Salloway, MD

Martin M. Zucker Professor of Psychiatry and Neurology

The Warren Alpert Medical School of Brown University
Memory & Aging Program, Butler Hospital

Stephen Salloway is Associate Director of the Brown Center for Alzheimer's Disease Research, the founding Director of the Memory and Aging Program at Butler Hospital, a Professor of Neurology, and the Martin M Zucker Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University. Dr. Salloway's research focuses on biomarker and drug development for prevention and early treatment of Alzheimer's disease, particularly the use of positron emission tomography (PET) ligands, plasma and CSF biomarkers for amyloid and tau to study the evolution of Alzheimer's pathophysiology in autosomal dominant and sporadic Alzheimer's disease. The MAP also has a lead role in testing targeted treatments, such as monoclonal antibodies, antisense oligonucleotides and novel ranti-inflammatory agents. He has authored or co-authored over 370 scientific articles or abstracts and is Editor of three books. These include lead authorship on pivotal trials that have featured in journals such as the Lancet and New England Journal of Medicine.



Gregory Klein, PhD

Expert Scientist, Head of Clinical Imaging, Neuroscience and Rare Diseases

Affiliation
Roche Pharmaceuticals, Basel, Switzerland

Overview: Gregory Klein is an Expert Scientist and Head of Clinical Imaging in the Neuroscience and Rare Diseases Discovery & Translational Medicine Center, at Roche Pharmaceuticals, Basel, Switzerland. Dr. Klein obtained his PhD from the University of California, Berkeley and held academic positions at the University of Washington, and the Lawrence Berkeley National Laboratory. He has over 30-years' experience in multiple facets of medical imaging and has published numerous original articles in this field.
His research interests include quantitative PET and MRI methods and their application in neuroscience, with a focus on Alzheimer's disease, as well as optimal use of these imaging biomarkers with other fluid, genetic and digital biomarkers in clinical trials.
Before joining Roche, Dr. Klein was Director of Molecular Imaging in Neuroscience at Bioclinica, Newark, CA. Dr. Klein is active in private/public consortia, currently chair of the ADNI Private Partner Scientific Board (PPSB), and has participated in the Critical Path Institute Alzheimer's and Parkinson's programs. He is also involved in standardization efforts such as the Quantitative Imaging Biomarkers Alliance (QIBA).